利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.021 秒)

    Rotomelt granulation
    1.
    发明授权
    Rotomelt granulation 失效
    Rotomelt造粒

    公开(公告)号：US5429825A

    公开(公告)日：1995-07-04

    申请号：US904940

    申请日：1992-06-26

    申请人： Joseph P. Reo ,  Edward J. Roche

    发明人： Joseph P. Reo ,  Edward J. Roche

    IPC分类号： A61K9/16 ,  B01J2/14 ,  B01J2/16

    CPC分类号： B01J2/16 ,  A61K9/1694 ,  B01J2/14

    摘要： A process for producing granules by rotomelt granulation comprising mixing at least one powdered pharmaceutically active material and a powdered excipient material within a zone wherein both powdered materials are maintained in a fluidized state by a rising stream of gas in an apparatus having a rapidly rotating horizontal-disk located within a vertical vessel wherein said gas is at a temperature sufficient to cause at least one powdered material to at least partially melt thereby causing said powdered materials to aggregate and form granules.

    摘要翻译： 一种通过滚筒造粒生产颗粒的方法，包括将至少一种粉末状药物活性物质和粉状赋形剂材料混合在一个区域内，其中两种粉末状材料在具有快速旋转水平 - 其中所述气体处于足以使至少一种粉末材料至少部分熔融的温度，从而使所述粉末材料聚集并形成颗粒。

    Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
    2.
    发明授权
    Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets 失效
    用于制备咀嚼型药片的旋涂和掩味涂层

    公开(公告)号：US5320855A

    公开(公告)日：1994-06-14

    申请号：US35140

    申请日：1993-03-19

    申请人： Edward J. Roche ,  Joseph P. Reo

    发明人： Edward J. Roche ,  Joseph P. Reo

    IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/50

    CPC分类号： A61K9/0056 ,  A61K9/1694 ,  A61K9/2081 ,  A61K9/5047

    摘要： Chewable medicament tablets are made from coated rotogranules of a medicament wherein the rotogranules are formed from a granulation mixture of medicament, e.g. ibuprofen, polyvinylpyrrolidone, sodium starch glycolate and sodium lauryl sulfate and the rotogranules are coated with hydroxyethyl cellulose or a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose and a process for making such tablets and a method of providing taste masking of medicaments utilizing such coated rotogranules in a tablet.

    摘要翻译： 可咀嚼的药物片剂由药物的包衣旋转颗粒制成，其中旋转粒剂由药物的制粒混合物形成， 布洛芬，聚乙烯吡咯烷酮，淀粉羟乙酸钠和十二烷基硫酸钠，并且所述旋转葡聚糖用羟乙基纤维素或羟乙基纤维素和羟丙基甲基纤维素的混合物包衣，以及制备这种片剂的方法以及使用这种涂覆的旋转粒剂在药物中提供掩蔽药物的方法 片剂。

    Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
    3.
    发明授权
    Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets 失效
    用于制备咀嚼型药片的旋涂和掩味涂层

    公开(公告)号：US5215755A

    公开(公告)日：1993-06-01

    申请号：US686723

    申请日：1991-04-17

    申请人： Edward J. Roche ,  Joseph P. Reo

    发明人： Edward J. Roche ,  Joseph P. Reo

    IPC分类号： A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K9/50

    CPC分类号： A61K9/2081 ,  A61K9/0056 ,  A61K9/1694 ,  A61K9/5047 ,  Y10S514/974

    摘要： Chewable medicament tablets are made from coated rotogranules of a medicament wherein the rotogranules are formed from a granulation mixture of medicament, e.g. ibuprofen, polyvinylpyrrolidone, sodium starch glycolate and sodium lauryl sulfate and the rotogranules are coated with hydroxyethyl cellulose or a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose and a process for making such tablets and a method of providing taste masking of medicaments utilizing such coated rotogranules in a tablet.

    摘要翻译： 可咀嚼的药物片剂由药物的包衣旋转颗粒制成，其中旋转粒剂由药物的制粒混合物形成， 布洛芬，聚乙烯吡咯烷酮，淀粉羟乙酸钠和十二烷基硫酸钠，并且所述旋转葡聚糖用羟乙基纤维素或羟乙基纤维素和羟丙基甲基纤维素的混合物包衣，以及制备这种片剂的方法以及使用这种涂覆的旋转粒剂在药物中提供掩蔽药物的方法 片剂。

    COATINGS FOR APPLYING SUBSTANCES ONTO SUBSTRATE CARRIER
    5.
    发明申请
    COATINGS FOR APPLYING SUBSTANCES ONTO SUBSTRATE CARRIER 审中-公开
    用于将物质应用于基板载体的涂料

    公开(公告)号：US20080299186A1

    公开(公告)日：2008-12-04

    申请号：US12130225

    申请日：2008-05-30

    申请人： Glenn E. Fritz ,  Joseph P. Reo ,  Mohammed A. Kabir

    发明人： Glenn E. Fritz ,  Joseph P. Reo ,  Mohammed A. Kabir

    IPC分类号： A61K9/48 ,  A61K31/137 ,  A61K9/20 ,  A61K47/10

    CPC分类号： A61K31/137

    摘要： Compositions of matter containing an active agent, and methods of manufacturing thereof, wherein the method comprises the step of coating a substrate with a coating composition comprising the active agent formulated for immediate release, wherein the coating composition does not contain an appreciable amount of cellulosic materials and preferably comprises polyvinyl alcohol or a polyvinyl alcohol derived copolymer.

    摘要翻译： 含有活性剂的物质组合物及其制备方法，其中该方法包括用包含配制成立即释放的活性剂的涂料组合物涂覆基材的步骤，其中涂料组合物不含有明显量的纤维素材料 优选包含聚乙烯醇或聚乙烯醇衍生的共聚物。

    Phenylephrine pharmaceutical formulations and compositions for colonic absorption
    6.
    发明授权
    Phenylephrine pharmaceutical formulations and compositions for colonic absorption 有权
    去氧肾上腺素药物制剂和用于结肠吸收的组合物

    公开(公告)号：US08956662B2

    公开(公告)日：2015-02-17

    申请号：US11756881

    申请日：2007-06-01

    申请人： David Monteith ,  John O'Mullane ,  Joseph P. Reo ,  Robert T. Nowak ,  Jiansheng Wan ,  Mohammed A. Kabir ,  Malaz A. Abutarif ,  Glenn E. Fritz

    发明人： David Monteith ,  John O'Mullane ,  Joseph P. Reo ,  Robert T. Nowak ,  Jiansheng Wan ,  Mohammed A. Kabir ,  Malaz A. Abutarif ,  Glenn E. Fritz

    IPC分类号： A61K31/137 ,  A61K31/4545 ,  A61K9/14 ,  A61P11/02 ,  A61P31/16 ,  A61P37/00 ,  A61K9/48 ,  A61K9/22 ,  A61K9/24 ,  A61K9/20

    CPC分类号： A61K31/137 ,  A61K9/167 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/4545 ,  A61K47/12 ,  A61K47/38

    摘要： The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma.

    摘要翻译： 本发明公开了一种药物组合物，其包含去氧肾上腺素或其药学上可接受的盐和用于口服给药的可溶性层，其中所述组合物通过在结肠中的吸收递送苯肾上腺素或其药学上可接受的盐。 药物组合物包含包含去氧肾上腺素或其药学上可接受的盐的核心和可溶性层，其处于时间依赖性，依赖于pH或结肠特异性的酶依赖性可溶解层，其降解以暴露核心以释放出去氧肾上腺素 结肠。 在一个优选实施例中，可侵蚀层包裹芯。 所述组合物任选地还包含可腐蚀层或其它附加层中的去氧肾上腺素。 药物组合物还可以包含一种或多种另外的治疗活性剂，其选自抗组胺剂，止痛剂，抗热解剂和非甾体抗炎剂中的一种或多种。 本发明还公开了通过结肠施用苯肾上腺素的方法，从而相对于血浆中的总去氧肾上腺素增加了治疗活性的非共轭去氧肾上腺素的生物可利用量。

    Oral liquid tolterodine composition
    9.
    发明授权
    Oral liquid tolterodine composition 失效
    口服液体托特罗定组合物

    公开(公告)号：US07101888B2

    公开(公告)日：2006-09-05

    申请号：US10647816

    申请日：2003-08-25

    申请人： Joseph P. Reo ,  Kathryn M. Kienle ,  Jennifer K. Fredrickson

    发明人： Joseph P. Reo ,  Kathryn M. Kienle ,  Jennifer K. Fredrickson

    IPC分类号： A01N43/90 ,  A61K31/519

    CPC分类号： A61K9/0095 ,  A61K31/137

    摘要： A pharmaceutical composition in a form of an orally deliverable liquid comprises water having in solution therein a pharmaceutically acceptable water-soluble salt of a tolterodine related compound at a therapeutically effective concentration in the composition. The composition has a pH of about 2 to about 6 and further comprises a sweetening agent and an antimicrobial agent at a concentration that is antimicrobially effective at the pH of the composition. The composition is useful for treating a muscarinic receptor mediated disorder, more particularly overactive bladder, in a subject by orally administering to the subject a therapeutically effective amount of the composition.

    摘要翻译： 口服递送液体形式的药物组合物包含在其溶液中的水，其中组胺中治疗有效浓度的药物可接受的托特罗定相关化合物的水溶性盐。 组合物的pH为约2至约6，并且还包含甜味剂和抗微生物剂，其浓度在组合物的pH下具有抗微生物效果。 该组合物可用于通过向受试者口服施用治疗有效量的组合物来治疗受试者中的毒蕈碱受体介导的病症，更具体地说是过度活跃的膀胱。